Darren J Kelly

List of Publications by Year
in descending order

209 papers	11,140 citations	20797 60 h-index	39638 94 g-index
211 all docs	211 docs citations	211 times ranked	11960 citing authors

#	Article	IF	Citations
1	Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes, 1999, 48, 2229-2239.	0.3	446
2	Obesity results in progressive atrial structural and electrical remodeling: Implications for atrial fibrillation. Heart Rhythm, 2013, 10, 90-100.	0.3	314
3	Does indoxyl sulfate, a uraemic toxin, have direct effects on cardiac fibroblasts and myocytes?. European Heart Journal, 2010, 31, 1771-1779.	1.0	256
4	The (Pro)Renin Receptor. Hypertension, 2009, 54, 261-269.	1.3	234
5	Retinal Neovascularization Is Prevented by Blockade of the Renin-Angiotensin System. Hypertension, 2000, 36, 1099-1104.	1.3	216
6	Proteinuria and the expression of the podocyte slit diaphragm protein, nephrin, in diabetic nephropathy: effects of angiotensin converting enzyme inhibition. Diabetologia, 2002, 45, 1572-1576.	2.9	204
7	Direct Actions of Urotensin II on the Heart. Circulation Research, 2003, 93, 246-253.	2.0	196
8	Angiotensin converting enzyme inhibition reduces retinal overexpression of vascular endothelial growth factor and hyperpermeability in experimental diabetes. Diabetologia, 2000, 43, 1360-1367.	2.9	173
9	Protein Kinase C Â Inhibition Attenuates the Progression of Experimental Diabetic Nephropathy in the Presence of Continued Hypertension. Diabetes, 2003, 52, 512-518.	0.3	173
10	Hypertension and atrial fibrillation: Evidence of progressive atrial remodeling with electrostructural correlate in a conscious chronically instrumented ovine model. Heart Rhythm, 2010, 7, 1282-1290.	0.3	168
11	Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats. Diabetologia, 2007, 50, 2398-2404.	2.9	165
12	Effect of angiotensin II type 1 receptor blockade on experimental hepatic fibrogenesis. Journal of Hepatology, 2001, 35, 376-385.	1.8	159
13	A new model of diabetic nephropathy with progressive renal impairment in the transgenic (mRen-2)27 rat (TGR). Kidney International, 1998, 54, 343-352.	2.6	153
14	Cardiorenal Syndrome. Circulation Research, 2012, 111, 1470-1483.	2.0	150
15	Chronic Kidney Disease-Induced Cardiac Fibrosis Is Ameliorated by Reducing Circulating Levels of a Non-Dialysable Uremic Toxin, Indoxyl Sulfate. PLoS ONE, 2012, 7, e41281.	1.1	138
16	Podocyte foot process broadening in experimental diabetic nephropathy: amelioration with renin-angiotensin blockade. Diabetologia, 2001, 44, 878-882.	2.9	137
17	Role of VEGF in maintaining renal structure and function under normotensive and hypertensive conditions. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 14448-14453.	3.3	137
18	Long-Term Administration of the Histone Deacetylase Inhibitor Vorinostat Attenuates Renal Injury in Experimental Diabetes through an Endothelial Nitric Oxide Synthase-Dependent Mechanism. American Journal of Pathology, 2011, 178, 2205-2214.	1.9	134

#	Article	IF	Citations
19	Pathological Expression of Renin and Angiotensin II in the Renal Tubule after Subtotal Nephrectomy. American Journal of Pathology, 1999, 155, 429-440.	1.9	132
20	eNOS Deficiency Predisposes Podocytes to Injury in Diabetes. Journal of the American Society of Nephrology: JASN, 2012, 23, 1810-1823.	3.0	124
21	Angiotensin type 2 receptor is expressed in the adult rat kidney and promotes cellular proliferation and apoptosis. Kidney International, 2000, 58, 2437-2451.	2.6	120
22	Decreased matrix degradation in diabetic nephropathy: effects of ACE inhibition on the expression and activities of matrix metalloproteinases. Diabetologia, 2002, 45, 268-275.	2.9	118
23	Targeting Fibrosis for the Treatment of Heart Failure: A Role for Transforming Growth Factorâ€‹<i>Î²</i>. Cardiovascular Therapeutics, 2012, 30, e30-40.	1.1	112
24	Expression of the slit-diaphragm protein, nephrin, in experimental diabetic nephropathy: differing effects of anti-proteinuric therapies. Nephrology Dialysis Transplantation, 2002, 17, 1327-1332.	0.4	109
25	PDGF signal transduction inhibition ameliorates experimental mesangial proliferative glomerulonephritis. Kidney International, 2001, 59, 1324-1332.	2.6	108
26	Inhibition of Platelet-Derived Growth Factor Promotes Pericyte Loss and Angiogenesis in Ischemic Retinopathy. American Journal of Pathology, 2004, 164, 1263-1273.	1.9	108
27	High glucose induces Smad activation via the transcriptional coregulator p300 and contributes to cardiac fibrosis and hypertrophy. Cardiovascular Diabetology, 2014, 13, 89.	2.7	108
28	Aminoguanidine Ameliorates Overexpression of Prosclerotic Growth Factors and Collagen Deposition in Experimental Diabetic Nephropathy. Journal of the American Society of Nephrology: JASN, 2001, 12, 2098-2107.	3.0	108
29	Inhibition of Protein Kinase Câ€"Î² by Ruboxistaurin Preserves Cardiac Function and Reduces Extracellular Matrix Production in Diabetic Cardiomyopathy. Circulation: Heart Failure, 2009, 2, 129-137.	1.6	106
30	Targeted inhibition of activin receptor-like kinase 5 signaling attenuates cardiac dysfunction following myocardial infarction. American Journal of Physiology - Heart and Circulatory Physiology, 2010, 298, H1415-H1425.	1.5	106
31	Thioredoxin interacting protein (TXNIP) regulates tubular autophagy and mitophagy in diabetic nephropathy through the mTOR signaling pathway. Scientific Reports, 2016, 6, 29196.	1.6	106
32	Tranilast attenuates cardiac matrix deposition in experimental diabetes: role of transforming growth factor-?. Cardiovascular Research, 2005, 65, 694-701.	1.8	102
33	The Renin-Angiotensin System Influences Ocular Endothelial Cell Proliferation in Diabetes. American Journal of Pathology, 2003, 162, 151-160.	1.9	100
34	PKC-Î²1 Mediates Glucose-Induced Akt Activation and TGF-Î²1 Upregulation in Mesangial Cells. Journal of the American Society of Nephrology: JASN, 2009, 20, 554-566.	3.0	100
35	COX-2 Inhibition and Retinal Angiogenesis in a Mouse Model of Retinopathy of Prematurity. , 2003, 44, 974.		98
36	Effects of a Rho kinase inhibitor on pressure overload induced cardiac hypertrophy and associated diastolic dysfunction. American Journal of Physiology - Heart and Circulatory Physiology, 2008, 294, H1804-H1814.	1.5	98

#	Article	IF	Citations
37	Effects of endothelin or angiotensin II receptor blockade on diabetes in the transgenic (mRen-2)27 rat. Kidney International, 2000, 57, 1882-1894.	2.6	96
38	Expression, Localization, and Function of the Thioredoxin System in Diabetic Nephropathy. Journal of the American Society of Nephrology: JASN, 2009, 20, 730-741.	3.0	96
39	ALT-946 and Aminoguanidine, Inhibitors of Advanced Glycation, Improve Severe Nephropathy in the Diabetic Transgenic (mREN-2)27 Rat. Diabetes, 2002, 51, 3283-3289.	0.3	95
40	Blockade of the Renin-Angiotensin and Endothelin Systems on Progressive Renal Injury. Hypertension, 2000, 36, 561-568.	1.3	93
41	Increased expression of urotensin II and urotensin II receptor in human diabetic nephropathy. American Journal of Kidney Diseases, 2004, 44, 826-831.	2.1	92
42	Short-term hypertension is associated with the development of atrial fibrillation substrate: A study in an ovine hypertensive model. Heart Rhythm, 2010, 7, 396-404.	0.3	90
43	Protein Kinase CÎ² Inhibition Attenuates Osteopontin Expression, Macrophage Recruitment, and Tubulointerstitial Injury in Advanced Experimental Diabetic Nephropathy. Journal of the American Society of Nephrology: JASN, 2005, 16, 1654-1660.	3.0	84
44	Atrial Arrhythmia in Ageing Spontaneously Hypertensive Rats: Unraveling the Substrate in Hypertension and Ageing. PLoS ONE, 2013, 8, e72416.	1.1	81
45	Relaxin Ameliorates Fibrosis in Experimental Diabetic Cardiomyopathy. Endocrinology, 2008, 149, 3286-3293.	1.4	80
46	Renal expression of transforming growth factor-Î² inducible gene-h3 (Î²ig-h3) in normal and diabetic rats11See Editorial by Border and Noble, p. 1390.. Kidney International, 1998, 54, 1052-1062.	2.6	79
47	Role of hyperlipidemia in progressive renal disease: Focus on diabetic nephropathy. Kidney International, 1999, 56, S31-S36.	2.6	79
48	Attenuation of tubular apoptosis by blockade of the renin-angiotensin system in diabetic Ren-2 rats. Kidney International, 2002, 61, 31-39.	2.6	76
49	Role of KrÃ¼ppel-like factor 6 in transforming growth factor-Î²1-induced epithelial-mesenchymal transition of proximal tubule cells. American Journal of Physiology - Renal Physiology, 2008, 295, F1388-F1396.	1.3	76
50	The renin-angiotensin system and the long-term complications of diabetes: pathophysiological and therapeutic considerations. Diabetic Medicine, 2003, 20, 607-621.	1.2	75
51	Microglia activation in the hypothalamic PVN following myocardial infarction. Brain Research, 2010, 1326, 96-104.	1.1	75
52	Endothelin Receptor Antagonism Ameliorates Mast Cell Infiltration, Vascular Hypertrophy, and Epidermal Growth Factor Expression in Experimental Diabetes. Circulation Research, 2000, 86, 158-165.	2.0	72
53	Functional, structural and molecular aspects of diastolic heart failure in the diabetic (mRen-2)27 rat. Cardiovascular Research, 2007, 76, 280-291.	1.8	72
54	High glucose transactivates the EGF receptor and up-regulates serum glucocorticoid kinase in the proximal tubule. Kidney International, 2005, 68, 985-997.	2.6	71

#	Article	IF	Citations
55	High Glucose-Induced Thioredoxin-Interacting Protein in Renal Proximal Tubule Cells Is Independent of Transforming Growth Factor-Î²1. American Journal of Pathology, 2007, 171, 744-754.	1.9	71
56	Myocardial infarction impairs renal function, induces renal interstitial fibrosis, and increases renal KIM-1 expression: implications for cardiorenal syndrome. American Journal of Physiology - Heart and Circulatory Physiology, 2012, 302, H1884-H1893.	1.5	71
57	Inhibition of protein kinase C reduces left ventricular fibrosis and dysfunction following myocardial infarction. Journal of Molecular and Cellular Cardiology, 2005, 39, 213-221.	0.9	70
58	Combination therapy of mesenchymal stem cells and serelaxin effectively attenuates renal fibrosis in obstructive nephropathy. FASEB Journal, 2015, 29, 540-553.	0.2	70
59	Mast cell infiltration and chemokine expression in progressive renal disease1. Kidney International, 2003, 64, 906-913.	2.6	69
60	Renal expression and localization of the facilitative glucose transporters GLUT1 and GLUT12 in animal models of hypertension and diabetic nephropathy. American Journal of Physiology - Renal Physiology, 2006, 290, F205-F213.	1.3	69
61	Plasmin is not protective in experimental renal interstitial fibrosis1. Kidney International, 2004, 66, 68-76.	2.6	67
62	Drug repurposing: Misconceptions, challenges, and opportunities for academic researchers. Science Translational Medicine, 2021, 13, eabd5524.	5.8	62
63	Tranilast Attenuates Structural and Functional Aspects of Renal Injury in the Remnant Kidney Model. Journal of the American Society of Nephrology: JASN, 2004, 15, 2619-2629.	3.0	61
64	Epidermal growth factor receptor inhibition attenuates early kidney enlargement in experimental diabetes. Kidney International, 2004, 66, 1805-1814.	2.6	60
65	Cardiac fibrosis in the ageing heart: Contributors and mechanisms. Clinical and Experimental Pharmacology and Physiology, 2017, 44, 55-63.	0.9	60
66	Heart Failure and Nephropathy: Catastrophic and Interrelated Complications of Diabetes. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 193-208.	2.2	58
67	Progression of tubulointerstitial injury by osteopontin-induced macrophage recruitment in advanced diabetic nephropathy of transgenic (mRen-2)27 rats. Nephrology Dialysis Transplantation, 2002, 17, 985-991.	0.4	57
68	Culture-Modified Bone Marrow Cells Attenuate Cardiac and Renal Injury in a Chronic Kidney Disease Rat Model via a Novel Antifibrotic Mechanism. PLoS ONE, 2010, 5, e9543.	1.1	55
69	Over-expression of platelet-derived growth factor in human diabetic nephropathy. Nephrology Dialysis Transplantation, 2003, 18, 1392-1396.	0.4	54
70	Tranilast attenuates diastolic dysfunction and structural injury in experimental diabetic cardiomyopathy. American Journal of Physiology - Heart and Circulatory Physiology, 2007, 293, H2860-H2869.	1.5	54
71	Inhibition of the epidermal growth factor receptor preserves podocytes and attenuates albuminuria in experimental diabetic nephropathy. Nephrology, 2011, 16, 573-581.	0.7	54
72	SB-267268, a Nonpeptidic Antagonist of Î±vÎ²3and Î±vÎ²5Integrins, Reduces Angiogenesis and VEGF Expression in a Mouse Model of Retinopathy of Prematurity. , 2006, 47, 1600.		53

#	Article	IF	Citations
73	Cardiac Repair With a Novel Population of Mesenchymal Stem Cells Resident in the Human Heart. Stem Cells, 2015, 33, 3100-3113.	1.4	53
74	Increased bradykinin and â€œnormalâ€• angiotensin peptide levels in diabetic Sprague-Dawley and transgenic (mRen-2)27 rats. Kidney International, 1999, 56, 211-221.	2.6	52
75	Intervention with Tranilast Attenuates Renal Pathology and Albuminuria in Advanced Experimental Diabetic Nephropathy. Nephron Physiology, 2003, 95, p83-p91.	1.5	52
76	Platelet-Derived Growth Factor Receptor Transactivation Mediates the Trophic Effects of Angiotensin II In Vivo. Hypertension, 2004, 44, 195-202.	1.3	52
77	Transforming Growth Factor-Â in Human Diabetic Nephropathy: Effects of ACE inhibition. Diabetes Care, 2006, 29, 2670-2675.	4.3	50
78	Effect of Ruboxistaurin on Urinary Transforming Growth Factor-Â in Patients With Diabetic Nephropathy and Type 2 Diabetes. Diabetes Care, 2007, 30, 995-996.	4.3	50
79	Contractile apparatus dysfunction early in the pathophysiology of diabetic cardiomyopathy. World Journal of Diabetes, 2015, 6, 943.	1.3	50
80	Expression during rat fetal development of GLUT12 - a member of the class III hexose transporter family. Anatomy and Embryology, 2002, 205, 441-452.	1.5	48
81	Advanced glycation end products decrease mesangial cell MMP-7: A role in matrix accumulation in diabetic nephropathy?. Kidney International, 2007, 72, 481-488.	2.6	48
82	Transcription Factors KrÃ¼ppel-Like Factor 6 and Peroxisome Proliferator-Activated Receptor-Î³ Mediate High Glucose-Induced Thioredoxin-Interacting Protein. American Journal of Pathology, 2009, 175, 1858-1867.	1.9	48
83	Angiotensin receptor neprilysin inhibition provides superior cardioprotection compared to angiotensin converting enzyme inhibition after experimental myocardial infarction. International Journal of Cardiology, 2018, 258, 192-198.	0.8	48
84	Macrophage Infiltration and Cellular Proliferation in the Non-Ischemic Kidney and Heart following Prolonged Unilateral Renal Ischemia. Nephron Physiology, 2007, 106, p54-p62.	1.5	47
85	Impact of type 2 diabetes and the metabolic syndrome on myocardial structure and microvasculature of men with coronary artery disease. Cardiovascular Diabetology, 2011, 10, 80.	2.7	47
86	Therapeutic effects of human STROâ€3â€selected mesenchymal precursor cells and their soluble factors in experimental myocardial ischemia. Journal of Cellular and Molecular Medicine, 2011, 15, 2117-2129.	1.6	46
87	Cardiorenal syndrome: Multiâ€organ dysfunction involving the heart, kidney and vasculature. British Journal of Pharmacology, 2020, 177, 2906-2922.	2.7	46
88	Differences in Myocardial Structure and Coronary Microvasculature Between Men and Women With Coronary Artery Disease. Hypertension, 2011, 57, 186-192.	1.3	45
89	Obesity Is Associated with Lower Coronary Microvascular Density. PLoS ONE, 2013, 8, e81798.	1.1	45
90	Evaluation and optimization of antifibrotic activity of cinnamoyl anthranilates. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 7003-7006.	1.0	44

#	Article	IF	Citations
91	Diastolic Dysfunction of Aging Is Independent of Myocardial Structure but Associated with Plasma Advanced Glycation End-Product Levels. PLoS ONE, 2012, 7, e49813.	1.1	44
92	Functional Interaction between Angiotensin II Receptor Type 1 and Chemokine (C-C Motif) Receptor 2 with Implications for Chronic Kidney Disease. PLoS ONE, 2015, 10, e0119803.	1.1	42
93	Renoprotective and antiâ€hypertensive effects of combined valsartan and perindopril in progressive diabetic nephropathy in the transgenic (mRenâ€2)27 rat. Nephrology Dialysis Transplantation, 2001, 16, 1343-1349.	0.4	40
94	Soluble epoxide hydrolase inhibition exerts beneficial anti-remodeling actions post-myocardial infarction. International Journal of Cardiology, 2013, 167, 210-219.	0.8	40
95	Tranilast attenuates the up-regulation of thioredoxin-interacting protein and oxidative stress in an experimental model of diabetic nephropathy. Nephrology Dialysis Transplantation, 2011, 26, 100-110.	0.4	39
96	SDF-1/CXCR4 Signaling Preserves Microvascular Integrity and Renal Function in Chronic Kidney Disease. PLoS ONE, 2014, 9, e92227.	1.1	39
97	Increased renal gene transcription of protein kinase C-Î² in human diabetic nephropathy: relationship to long-term glycaemic control. Diabetologia, 2008, 51, 668-674.	2.9	38
98	Localization of Secreted Protein Acidic and Rich in Cysteine (SPARC) Expression in the Rat Eye. Connective Tissue Research, 1999, 40, 295-303.	1.1	37
99	Tranilast reduces mesenteric vascular collagen deposition and chymase-positive mast cells in experimental diabetes. Journal of Diabetes and Its Complications, 2004, 18, 309-315.	1.2	37
100	Vitamin D2 supplementation induces the development of aortic stenosis in rabbits: Interactions with endothelial function and thioredoxin-interacting protein. European Journal of Pharmacology, 2008, 590, 290-296.	1.7	37
101	The cardiac (pro)renin receptor is primarily expressed in myocyte transverse tubules and is increased in experimental diabetic cardiomyopathy. Journal of Hypertension, 2011, 29, 1175-1184.	0.3	37
102	Dynamic Synchrotron Imaging of Diabetic Rat Coronary Microcirculation In Vivo. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 370-377.	1.1	37
103	Subtotal nephrectomy accelerates pathological cardiac remodeling post-myocardial infarction: Implications for cardiorenal syndrome. International Journal of Cardiology, 2013, 168, 1866-1880.	0.8	37
104	A Purpose-Synthesised Anti-Fibrotic Agent Attenuates Experimental Kidney Diseases in the Rat. PLoS ONE, 2012, 7, e47160.	1.1	37
105	FT011, a new antiâ€fibrotic drug, attenuates fibrosis and chronic heart failure in experimental diabetic cardiomyopathy. European Journal of Heart Failure, 2012, 14, 549-562.	2.9	36
106	Nitrosative Stress as a Modulator of Inflammatory Change in a Model of Takotsubo Syndrome. JACC Basic To Translational Science, 2018, 3, 213-226.	1.9	36
107	Vascular endothelial growth factor expression and glomerular endothelial cell loss in the remnant kidney model. Nephrology Dialysis Transplantation, 2003, 18, 1286-1292.	0.4	35
108	Aliskiren: a novel renoprotective agent or simply an alternative to ACE inhibitors?. Kidney International, 2009, 76, 23-31.	2.6	35

#	Article	IF	Citations
109	Ramipril retards development of aortic valve stenosis in a rabbit model: mechanistic considerations. British Journal of Pharmacology, 2011, 162, 722-732.	2.7	35
110	High glucose induces macrophage inflammatory protein-3Â in renal proximal tubule cells via a transforming growth factor-Â1 dependent mechanism. Nephrology Dialysis Transplantation, 2007, 22, 3147-3153.	0.4	34
111	Elevated cannabinoid receptor 1 and G proteinâ€coupled receptor 55 expression in proximal tubule cells and whole kidney exposed to diabetic conditions. Clinical and Experimental Pharmacology and Physiology, 2015, 42, 256-262.	0.9	34
112	In vivo visualization of albumin degradation in the proximal tubule. Kidney International, 2008, 74, 1480-1486.	2.6	33
113	Increased tissue kallikrein levels in type 2 diabetes. Diabetologia, 2010, 53, 779-785.	2.9	33
114	Acute Rho-kinase inhibition improves coronary dysfunction in vivo, in the early diabetic microcirculation. Cardiovascular Diabetology, 2013, 12, 111.	2.7	33
115	Atrial Remodeling in an Ovine Model of Anthracycline-Induced Nonischemic Cardiomyopathy: Remodeling of the Same Sort. Journal of Cardiovascular Electrophysiology, 2010, 22, no-no.	0.8	32
116	Neonatal calyceal dilation and renal fibrosis resulting from loss of Adamts-1 in mouse kidney is due to a developmental dysgenesis. Nephrology Dialysis Transplantation, 2005, 20, 419-423.	0.4	31
117	The role of dihydrosphingolipids in disease. Cellular and Molecular Life Sciences, 2019, 76, 1107-1134.	2.4	31
118	Effects on protein kinase C-Î² inhibition on glomerular vascular endothelial growth factor expression and endothelial cells in advanced experimental diabetic nephropathy. American Journal of Physiology - Renal Physiology, 2007, 293, F565-F574.	1.3	30
119	The Uremic Toxin Adsorbent AST-120 Abrogates Cardiorenal Injury Following Myocardial Infarction. PLoS ONE, 2013, 8, e83687.	1.1	30
120	Early and Delayed Tranilast Treatment Reduces Pathological Fibrosis Following Myocardial Infarction. Heart Lung and Circulation, 2013, 22, 122-132.	0.2	28
121	Tranilast attenuates vascular hypertrophy, matrix accumulation and growth factor overexpression in experimental diabetes. Diabetes and Metabolism, 2003, 29, 386-392.	1.4	27
122	Atrial protective effects of n-3 polyunsaturated fatty acids: A long-term study in ovine chronic heart failure. Heart Rhythm, 2011, 8, 575-582.	0.3	27
123	Contribution of microRNA to pathological fibrosis in cardio-renal syndrome: impact of uremic toxins. Physiological Reports, 2015, 3, e12371.	0.7	27
124	Diastolic dysfunction is initiated by cardiomyocyte impairment ahead of endothelial dysfunction due to increased oxidative stress and inflammation in an experimental prediabetes model. Journal of Molecular and Cellular Cardiology, 2019, 137, 119-131.	0.9	27
125	The Interaction between the Renin-Angiotensin System and Vascular Endothelial Growth Factor in the Pathogenesis of Retinal Neovascularization in Diabetes. Journal of Vascular Research, 2001, 38, 527-535.	0.6	26
126	Modulation of osteopontin in proteinuria-induced renal interstitial fibrosis. Journal of Pathology, 2005, 207, 483-492.	2.1	26

#	Article	IF	Citations
127	The roles of Kruppel-like factor 6 and peroxisome proliferator-activated receptor-Î³ in the regulation of macrophage inflammatory protein-3Î± at early onset of diabetes. International Journal of Biochemistry and Cell Biology, 2011, 43, 383-392.	1.2	26
128	Adrenaline cells of the rat adrenal cortex and medulla contain renin and prorenin. Molecular and Cellular Endocrinology, 1996, 119, 175-184.	1.6	25
129	Thioredoxin-Interacting Protein: A Potential Therapeutic Target for Treatment of Progressive Fibrosis in Diabetic Nephropathy. Nephron, 2015, 129, 109-127.	0.9	25
130	Angiotensin II-induced proteinuria and expression of the podocyte slit pore membrane protein, nephrin. Nephrology Dialysis Transplantation, 2004, 19, 262-263.	0.4	24
131	Fas-induced apoptosis is a feature of progressive diabetic nephropathy in transgenic (mRen-2)27 rats: Attenuation with renin-angiotensin blockade. Nephrology, 2004, 9, 7-13.	0.7	24
132	Cannabinoid Receptor 2 Expression in Human Proximal Tubule Cells is Regulated by Albumin Independent of ERK1/2 Signaling. Cellular Physiology and Biochemistry, 2013, 32, 1309-1319.	1.1	24
133	Renin processing and secretion in adrenal and retina of transgenic (mREN-2)27 rats. Kidney International, 1994, 46, 1583-1587.	2.6	23
134	Combination therapy with tranilast and angiotensin-converting enzyme inhibition provides additional renoprotection in the remnant kidney model. Kidney International, 2006, 69, 1954-1960.	2.6	23
135	3â€²,4â€²-Dihydroxyflavonol Antioxidant Attenuates Diastolic Dysfunction and Cardiac Remodeling in Streptozotocin-Induced Diabetic m(Ren2)27 Rats. PLoS ONE, 2011, 6, e22777.	1.1	23
136	Aliskiren increases bradykinin and tissue kallikrein mRNA levels in the heart. Clinical and Experimental Pharmacology and Physiology, 2011, 38, 623-631.	0.9	23
137	Cost-Effectiveness of Renal Denervation Therapy for Treatment-Resistant Hypertension: A Best Case Scenario. American Journal of Hypertension, 2018, 31, 1156-1163.	1.0	23
138	Angiotensin II and the Cardiac Complications of Diabetes Mellitus. Current Pharmaceutical Design, 2007, 13, 2721-2729.	0.9	22
139	Protein kinase C-Â inhibition attenuates the progression of nephropathy in non-diabetic kidney disease. Nephrology Dialysis Transplantation, 2009, 24, 1782-1790.	0.4	21
140	Reduced microvascular density in non-ischemic myocardium of patients with recent non-ST-segment-elevation myocardial infarction. International Journal of Cardiology, 2013, 167, 1027-1037.	0.8	21
141	Characterisation of a thymic reninâ€"angiotensin system in the transgenic m(Ren-2)27 rat. Molecular and Cellular Endocrinology, 2002, 194, 201-209.	1.6	20
142	Widespread Coronary Dysfunction in the Absence of HDL Receptor SR-B1 in an Ischemic Cardiomyopathy Mouse Model. Scientific Reports, 2017, 7, 18108.	1.6	20
143	Does vascular endothelial growth factor (VEGF) play a role in the pathogenesis of minimal change disease?. Nephrology Dialysis Transplantation, 2003, 18, 2293-2299.	0.4	19
144	Cells expressing the stem cell factor receptor, c-kit, contribute to neoangiogenesis in diabetes. Diabetes and Vascular Disease Research, 2005, 2, 76-80.	0.9	18

#	Article	IF	Citations
145	Cardiorenal syndrome: Pathophysiology, preclinical models, management and potential role of uraemic toxins. Clinical and Experimental Pharmacology and Physiology, 2012, 39, 692-700.	0.9	18
146	Chronic intermittent hypoxia accelerates coronary microcirculatory dysfunction in insulin-resistant Goto-Kakizaki rats. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2016, 311, R426-R439.	0.9	18
147	Characterization of cardiac remodeling in a large animal â€œone-kidney, one-clipâ€• hypertensive model. Blood Pressure, 2010, 19, 119-125.	0.7	17
148	The Anti-fibrotic Hormone Relaxin is not Reno-protective, Despite Being Active, in an Experimental Model of Type 1 Diabetes. Protein and Peptide Letters, 2013, 20, 1029-1038.	0.4	17
149	Renal cellular hypoxia in adenineâ€induced chronic kidney disease. Clinical and Experimental Pharmacology and Physiology, 2016, 43, 896-905.	0.9	17
150	Effects of Low-Dose and Early versus Late Perindopril Treatment on the Progression of Severe Diabetic Nephropathy in (mREN-2)27 Rats. Journal of the American Society of Nephrology: JASN, 2002, 13, 684-692.	3.0	17
151	Angiotensin II influences ovarian follicle development in the transgenic (mRen-2)27 and Sprague-Dawley rat. Journal of Endocrinology, 2004, 180, 311-324.	1.2	16
152	The differential regulation of Smad7 in kidney tubule cells by connective tissue growth factor and transforming growth factor-beta1. Nephrology, 2007, 12, 267-274.	0.7	16
153	Chronic urotensin II receptor antagonist treatment does not alter hypertrophy or fibrosis in a rat model of pressure-overload hypertrophy. Peptides, 2010, 31, 1523-1530.	1.2	16
154	<scp>FT</scp>23, an orally active antifibrotic compound, attenuates structural and functional abnormalities in an experimental model of diabetic cardiomyopathy. Clinical and Experimental Pharmacology and Physiology, 2012, 39, 650-656.	0.9	16
155	Attenuation of Armanniâ€“Ebstein lesions in a rat model of diabetes by a new anti-fibrotic, anti-inflammatory agent, FT011. Diabetologia, 2013, 56, 675-679.	2.9	16
156	3â€²,4â€²-Bis-difluoromethoxycinnamoylanthranilate (FT061): An orally-active antifibrotic agent that reduces albuminuria in a rat model of progressive diabetic nephropathy. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 6868-6873.	1.0	16
157	Myosin Heads Are Displaced from Actin Filaments in the In Situ Beating Rat Heart in Early Diabetes. Biophysical Journal, 2013, 104, 1065-1072.	0.2	16
158	Calibrated integrated backscatter and myocardial fibrosis in patients undergoing cardiac surgery. Open Heart, 2015, 2, e000278.	0.9	15
159	SPARC Gene Expression Is Increased in Diabetes-Related Mesenteric Vascular Hypertrophy. Microvascular Research, 2000, 59, 61-71.	1.1	14
160	Chronic Rho-kinase inhibition improves left ventricular contractile dysfunction in early type-1 diabetes by increasing myosin cross-bridge extension. Cardiovascular Diabetology, 2015, 14, 92.	2.7	14
161	FT011, a Novel Cardiorenal Protective Drug, Reduces Inflammation, Gliosis and Vascular Injury in Rats with Diabetic Retinopathy. PLoS ONE, 2015, 10, e0134392.	1.1	14
162	Aryl Hydrocarbon Receptor Inhibition Restores Indoxyl Sulfate-Mediated Endothelial Dysfunction in Rat Aortic Rings. Toxins, 2022, 14, 100.	1.5	13

#	Article	IF	Citations
163	Mitogen activated protein kinase signaling in the kidney: target for intervention?. Signal Transduction, 2006, 6, 32-53.	0.7	12
164	Role of the EGF receptor in PPARÎ^3-mediated sodium and water transport in human proximal tubule cells. Diabetologia, 2013, 56, 1174-1182.	2.9	12
165	Combination Angiotensin Converting Enzyme and Direct Renin Inhibition in Heart Failure following Experimental Myocardial Infarction. Cardiovascular Therapeutics, 2013, 31, 84-91.	1.1	12
166	Role of the eNOS-NO System in Regulating the Antiproteinuric Effects of VEGF Receptor 2 Inhibition in Diabetes. BioMed Research International, 2013, 2013, 1-8.	0.9	12
167	Novel approaches to the treatment of progressive renal disease. Current Opinion in Pharmacology, 2001, 1, 183-189.	1.7	11
168	A new anti-fibrotic drug attenuates cardiac remodeling and systolic dysfunction following experimental myocardial infarction. International Journal of Cardiology, 2013, 168, 1174-1185.	0.8	11
169	Impaired cardiac anti-oxidant activity in diabetes: human and correlative experimental studies. Acta Diabetologica, 2014, 51, 771-782.	1.2	11
170	Vasoactive Renal Factors and the Progression of Diabetic Nephropathy. Current Pharmaceutical Design, 2004, 10, 3373-3384.	0.9	11
171	Inhibition of apoptosis signal-regulating kinase 1 ameliorates left ventricular dysfunction by reducing hypertrophy and fibrosis in a rat model of cardiorenal syndrome. International Journal of Cardiology, 2020, 310, 128-136.	0.8	10
172	Clinically Relevant Models of Diabetic Cardiac Complications. Circulation Research, 2007, 101, e78.	2.0	9
173	Perindopril attenuates tubular hypoxia and inflammation in an experimental model of diabetic nephropathy in transgenic <i>Renâ€•2</i> rats. Nephrology, 2008, 13, 721-729.	0.7	9
174	Role of Statins in Diabetes Complications. Current Diabetes Reviews, 2009, 5, 165-170.	0.6	9
175	Inhibition of Apoptosis Signal-Regulating Kinase 1 Attenuates Myocyte Hypertrophy and Fibroblast Collagen Synthesis. Heart Lung and Circulation, 2019, 28, 495-504.	0.2	9
176	Tranilast Ameliorates Experimental Mesangial Proliferative Glomerulonephritis. Nephron Experimental Nephrology, 2008, 109, e1-e7.	2.4	8
177	Chloride channel ClC-5 binds to aspartyl aminopeptidase to regulate renal albumin endocytosis. American Journal of Physiology - Renal Physiology, 2015, 308, F784-F792.	1.3	8
178	Effect of Atorvastatin on Cardiac Remodelling and Mortality in Rats Following Hyperglycemia and Myocardial Infarction. International Journal of Cardiology, 2010, 143, 353-360.	0.8	7
179	Urotensin II and the kidney. Current Opinion in Nephrology and Hypertension, 2013, 22, 107-112.	1.0	7
180	Apoptosis signal-regulating kinase 1 inhibition reverses deleterious indoxyl sulfate-mediated endothelial effects. Life Sciences, 2021, 272, 119267.	2.0	7

#	Article	IF	Citations
181	Spironolactone mitigates, but does not reverse, the progression of renal fibrosis in a transgenic hypertensive rat. Physiological Reports, 2020, 8, e14448.	0.7	7
182	Chronic kidney disease with comorbid cardiac dysfunction exacerbates cardiac and renal damage. Journal of Cellular and Molecular Medicine, 2018, 22, 628-645.	1.6	6
183	Renin Inhibition. Hypertension, 2005, 46, 471-472.	1.3	5
184	Transcriptomic analysis of choroidal neovascularization reveals dysregulation of immune and fibrosis pathways that are attenuated by a novel anti-fibrotic treatment. Scientific Reports, 2022, 12, 859.	1.6	5
185	Experimental diabetic nephropathy: Is it relevant to the human disease. Nephrology, 2000, 5, 177-185.	0.7	4
186	Drug therapy for the cardiac complications of diabetes. Drug Discovery Today: Therapeutic Strategies, 2004, 1, 195-200.	0.5	4
187	Progressive diabetic nephropathy in the Ren-2 rat. American Journal of Physiology - Renal Physiology, 2007, 292, F1662-F1662.	1.3	4
188	High glucose induced endothelial cell growth inhibition is associated with an increase in TGFÎ²1 secretion and inhibition of Ras prenylation via suppression of the mevalonate pathway. International Journal of Biochemistry and Cell Biology, 2009, 41, 561-569.	1.2	4
189	Protein kinase C ÃŸ inhibition ameliorates experimental mesangial proliferative glomerulonephritis. Nephrology, 2011, 16, no-no.	0.7	4
190	The effect of dihydroceramide desaturase 1 inhibition on endothelial impairment induced by indoxyl sulfate. Vascular Pharmacology, 2021, 141, 106923.	1.0	4
191	Glucose transporters in animal models of diabetes and hypertension. American Journal of Physiology - Renal Physiology, 2006, 291, F702-F703.	1.3	3
192	BK virus RNA can be detected in archival renal transplant biopsies using the reverse trancription polymerase chain reaction. Nephrology Dialysis Transplantation, 2009, 24, 661-666.	0.4	3
193	Prescription of physical activity in the management of high blood pressure in Australian general practices. Journal of Human Hypertension, 2019, 33, 50-56.	1.0	3
194	Î²-blockade prevents coronary macro- and microvascular dysfunction induced by a high salt diet and insulin resistance in the Gotoâ€“Kakizaki rat. Clinical Science, 2021, 135, 327-346.	1.8	3
195	Nephropathy in type 2 diabetes: current therapeutic strategies. Nephrology, 2001, 6, 266-269.	0.7	2
196	Angiotensin receptor neprilysin inhibitor LCZ696: pharmacology, pharmacokinetics and clinical development. Future Cardiology, 2017, 13, 103-115.	0.5	1
197	NP202 treatment improves left ventricular systolic function and attenuates pathological remodelling following chronic myocardial infarction. Life Sciences, 2022, 289, 120220.	2.0	1
198	Angiotensin-converting enzyme inhibition attenuates renal platelet-derived growth factor gene expression and cell proliferation in subtotal nephrectomy. Nephrology, 2001, 6, 290-297.	0.7	0

#	Article	IF	Citations
199	Sandford Lloyd Skinner (1933â€"2005). Hypertension, 2005, 46, 452-453.	1.3	0
200	Diabetic nephropathy without the diabetes: If not hyperglycaemia, then what? (Editorial). Nephrology, 2007, 12, 67-68.	0.7	0
201	RE: ASK1, a new target in treating cardiorenal syndrome (CRS). International Journal of Cardiology, 2020, 316, 207.	0.8	0
202	RE: Inhibition of apoptosis signal-regulating kinase 1 might be a novel therapeutic target in the treatment of cardiorenal syndrome. International Journal of Cardiology, 2021, 323, 260.	0.8	0
203	RE: Blockade of apoptosis signal-regulating kinase 1 ameliorates cardiac dysfunction in cardiorenal syndrome via enhancing angiogenesis. International Journal of Cardiology, 2021, 326, 156.	0.8	0
204	Protective role for Epidermal Growth Factor in Advanced Diabetic Nephropathy of Transgenic (mRenâ€2)27 rats. Nephrology, 2000, 5, A102-A102.	0.7	0
205	THE IMPORTANCE OF BLOCKADE OF THE RENIN ANGIOTENSIN AND ENDOTHELIN SYSTEMS ON PROGRESSIVE RENAL INJURY IN SUBTOTALLY NEPHRECTOMISED RATS: USE OF COMBINATION REGIMENS. Nephrology, 2000, 5, A109-A109.	0.7	0
206	Protective role for Epidermal Growth Factor in Advanced Diabetic Nephropathy of Transgenic (mRenâ€2)27 rats. Nephrology, 2000, 5, A102-A102.	0.7	0
207	Predictors of Atrial Fibrosis in an Ovine Model of Obesity. Journal of Arrhythmia, 2011, 27, OP44_2.	0.5	0
208	Obesity and Atrial Fibrillation: A Chronic Ovine Study. Journal of Arrhythmia, 2011, 27, YIAB_1.	0.5	0
209	Rho Kinase Inhibition Improves Cardiac Crossâ€Bridge Dynamics in Early Diabetic Cardiomyopathy. FASEB Journal, 2015, 29, 799.7.	0.2	0